🌟 MSInsight at CHU HealthTech Connexion Day #3 2024! 🌟 We’re thrilled to announce that MSInsight will attend the CHU HealthTech Connexion Day 2024 and France Biotech on December 2nd, 2024! Our very own Arnaud Cutivet (CEO) and Toky Ratovomanana (CTO) will represent MSInsight at this prestigious event. This is an incredible opportunity for us to showcase our groundbreaking work in microsatellite instability (MSI) detection and precision oncology, and we’re excited to connect with innovators, experts, and stakeholders in the health tech ecosystem. 🛠️ Visit Our Booth We’ll have our very own booth where you can discover MSIcare, our innovative software that uses next-generation sequencing to detect MSI and helps predict the effectiveness of precision cancer treatments. 💡 Let’s Connect! Whether you’re interested in our technology, want to discuss collaboration opportunities, or are just curious about what we do, we’d love to meet you. Let’s make strides together to advance precision medicine! See you in Lille, France! 👋 #HealthTech #Innovation #PrecisionOncology #MSInsight #MSIcare #CHUHealthTechConnexionDay2024
MSInsight
Fabrication d’équipements médicaux
Unlocking the Power of Genomics: Advancing Cancer Care and Precision Medicine
À propos
MSInsight, a French health-tech company, empowers the fight against cancer by revealing actionable information from the genome. We are committed to developing a portfolio of state-of-the-art diagnostic solutions for Microsatellite Instability (MSI) status. MSI has been shown to be an indicator of treatment response, especially for immune checkpoint inhibitors, and as an important pan-cancer biomarker. We aim to propose bioinformatic tools for delivering insights on microsatellite mutational variations using Next-Generation Sequencing (NGS) data. Our flagship product, MSIcare, will be available as a robust diagnostic, prognostic, and theranostic assistant for guiding clinical decision-making.
- Site web
-
http://www.msinsight.tech
Lien externe pour MSInsight
- Secteur
- Fabrication d’équipements médicaux
- Taille de l’entreprise
- 2-10 employés
- Siège social
- Paris
- Type
- Société civile/Société commerciale/Autres types de sociétés
- Fondée en
- 2022
- Domaines
- Microsatellite Instability, Next-Generation Sequencing, Diagnostic Test, Bioinformatics, Oncology, Precision Medicine, Hereditary Cancer et Defective Mismatch Repair
Lieux
-
Principal
Obtenir l’itinéraire
Paris, FR
Employés chez MSInsight
-
Arnaud Cutivet
#deeptech #oncology #genomic #precision medicine - Chief Executive Officer
-
Toky Ratovomanana
PhD in Cancer Genomics, Head of Bioinformatics at MSInsight
-
Sydney Normand
Market Access Specialist | MSc Health Management and Data Intelligence - EMLYON Business School
-
Mélyna K.
QA/RA Engineer
Nouvelles
-
🚨 We're Hiring: Lead Developer Full Stack (H/F) 🚨 At MSInsight, we are transforming cancer care with innovation and technology. As a fast-growing health tech startup based in Paris and Lyon, we empower oncologists to choose the best treatment for each cancer patient through MSIcare, our groundbreaking bioinformatics and AI solution. Now, we’re looking for a Lead Developer - Full Stack, to join our mission and help us save lives with personalized medicine. 🧬💡 In this role, you will: - Lead and mentor a team of talented developers. - Build and optimize applications using React, Node.js, and AWS. - Collaborate with product and R&D teams to design impactful features. - Drive scalability, security, and performance in everything you develop. We’re looking for: - A passionate full-stack developer with experience in modern technologies. - Expertise in serverless architecture, cloud computing, and CI/CD pipelines. - Someone who thrives in a collaborative, mission-driven environment. 🌍 Location: Paris or Lyon (with remote options) 📧 Apply now: Send your CV to jobs@msinsight.tech Join us to redefine cancer diagnostics and make a global impact. Together, we can change lives.
-
🌟 Exciting News! 🌟 We’re thrilled to announce that MSInsight has been named one of Hello Tomorrow’s Deep Tech Pioneers! Selected from 4,600 applications from over 120 countries, this recognition is a huge milestone for our team as we continue to innovate and push boundaries in genomics and health tech. Join us at the 10th Hello Tomorrow Global Summit on March 13-14, 2025, where we’ll connect with top innovators, industry leaders, and investors worldwide. It’s an incredible opportunity to showcase our work, exchange ideas, and explore collaborations that can drive real-world impact. We’re just getting started! 🌍🚀 👉 Follow along and support our journey as we move closer to becoming a Finalist in the Global Challenge. https://lnkd.in/eD4wdRj4 #HelloTomorrow #DeepTechPioneer #Innovation #HealthTech #Genomics #DeepTechDays
-
-
🎉 We’re proud to support our intern, Sydney Normand, who recently attended the Journées de l'Innovation en Biologie event in Paris! Sydney, a student in Health Management and Data Intelligence at EMLyon, joined the event to gain deeper insights into the latest innovations in genomics and biomarker research. At MSInsight, we value the curiosity and passion our team members bring to the field. Sydney’s experience at JIB, learning about cutting-edge diagnostics and advancements in personalized medicine, strengthens her contributions to our work in precision genomics. #JIB2024 #Genomics #PrecisionMedicine #FutureLeaders #MSInsight
Market Access Specialist | MSc Health Management and Data Intelligence - EMLYON Business School
🌐 I recently attended the Journées de l'Innovation en Biologie event in Paris, where the focus was on the transformative potential of genomics and biomarkers in personalized medicine. Key discussions covered: MSI-H/dMMR Status in Cancer: We explored the crucial role of microsatellite instability (MSI) in cancer diagnostics, particularly in colorectal cancer. MSI-high (MSI-H) and mismatch repair deficiency (dMMR) are associated with better responses to immunotherapies, such as Pembrolizumab, highlighting the importance of accurate biomarker testing for treatment selection. Biomarker Types and Classes: From predictive and diagnostic biomarkers to safety and pharmacodynamic biomarkers, each type plays a unique role in understanding disease progression, treatment response, and patient safety. These tools are vital for tailoring treatments to individual patients and advancing precision medicine. It was inspiring to see how innovations in liquid biopsy testing and next-generation sequencing are driving progress in personalized healthcare. #JIB2024 #BiomedicalInnovation #Genomics #PrecisionMedicine
-
-
📰 We’re thrilled to share that our CEO, Arnaud Cutivet, had the opportunity to speak with mind Health for an insightful discussion on the future of genomic medicine! In their latest issue, mind Health dives deep into the impact of genomics on personalized medicine, highlighting the significant strides in cancer diagnostics and rare disease research. A big thank you to the mind Health’s team—Clarisse Treilles, Romain Bonfillon, Coralie Baumard, and Sophie Deplus—for shedding light on this crucial topic and giving us the platform to share our vision for the future of healthcare! #GenomicMedicine #PersonalizedHealthcare #CancerDiagnostics #MSInsight
Bonjour à toutes et à tous ! Cette semaine, au sommaire du numéro 303 de mind Health : [ESSENTIEL] La génomique, une voie d’avenir de la médecine personnalisée La médecine génomique a connu un fort essor ces dernières années, en particulier dans les filières des maladies rares et des cancers. Les progrès technologiques de séquençage et les stratégies mises en place à l’échelle nationale et européenne pour élaborer des parcours de soins et monter des structures de recherche contribuent à faire sortir la génomique du champ de la science-fiction. https://lnkd.in/gHGZ22gb Frédérique Nowak Arnaud Cutivet Dr. Amaury Martin [ENTRETIEN] Laurie Soffiati (Cnam) : “L’enjeu principal est d’accompagner et d’encadrer le déploiement des outils d’intelligence artificielle” Fin octobre 2022, l’Assurance Maladie a créé un département Télésanté et Innovation numérique. Composé de six personnes et directement rattaché à Marguerite Cazeneuve, la directrice déléguée à la gestion et à l'organisation des soins, il permet à l’Assurance Maladie d’élaborer et de piloter sa stratégie en la matière. Laurie Soffiati, sa responsable, revient pour mind Health sur les premières réalisations du département et dévoile ses prochaines expérimentations. https://lnkd.in/gNvtzMFx Caisse nationale de l’Assurance Maladie Marguerite Cazeneuve [START-UP A LA LOUPE] Okomera : les organoïdes pour accélérer la découverte de médicaments Fondée en 2020 au sein de l’Institut Pasteur et de l’École polytechnique, Okomera vise à améliorer les traitements contre le cancer. À la mi-octobre la biotech vient d’obtenir une subvention de 1,5 M€ de Bpifrance pour développer un nouveau test de criblage CRISPR. Sidarth Radjou, son CEO, détaille à mind Health les ambitions de la start-up. https://lnkd.in/gAE3bVrA [ANALYSE] Utilisation secondaire des données de santé : le temps de l’accélération Le 4 octobre dernier, Ludovic Lamarsalle, cofondateur de la CRO Heva, détaillait à mind Health la société de conseil qu’il venait de fonder. Ce spécialiste de l’analyse de la donnée de santé revient sur les principaux défis posés par l’utilisation secondaire de ces données, alors que se termine la phase de consultation publique sur la “Stratégie interministérielle pour construire notre patrimoine national des données de santé”. https://lnkd.in/gsUqkP_p Et l'actualité du secteur avec : Axomove, Haute Autorité de Santé, General Catalyst, Quantum Genomics, Cure51, etc. Ce numéro a été préparé par : Romain Bonfillon, Coralie Baumard, Clarisse Treilles et Sophie Deplus.
-
-
🌟 Movember for Men’s Health 🌟 This month, MSInsight is raising awareness of cancers affecting men, including prostate, testicular, colorectal, and lung cancer. Movember is a reminder to prioritize screenings and proactive health. Together, let’s support men’s health and drive awareness for early detection and care. 💙 #Movember #MensHealth #CancerAwareness #MSInsight
-
-
🎃👻 Halloween at MSInsight! Whether in Paris or Lyon, the MSInsight team celebrates with costumes, laughs, and a shared spirit of fun and creativity. From spooky costumes to festive office decorations, we embraced Halloween as a chance to connect, even from different cities. Wishing everyone a happy and safe Halloween! 🎃✨ #Halloween2024 #TeamCulture #MSInsight
-
🔍 Myth-Busting: Does MSI Testing Only Benefit Patients in Advanced Cancer Stages? ❌ Myth: MSI testing is only useful for patients with advanced or metastatic cancer. ✅ Fact: MSI testing is valuable at any stage of cancer. It can help identify patients who may benefit from specific therapies, such as immunotherapy, early in their diagnosis. The insights gained from MSI testing allow physicians to make more informed decisions and personalize treatment plans, potentially improving outcomes even in the early stages of cancer. At MSInsight, we believe in the power of personalized medicine for all patients, at every step of their cancer journey. Our MSIcare solution helps healthcare providers tailor treatments from the start. #MSI #MythBusting #PersonalizedMedicine #MSIcare #GenomicTesting #CancerCare #MSInsight #EarlyCancerDetection
-
💡 The Future of Personalized Medicine Starts with Genomic Testing! At MSInsight, we’re passionate about advancing healthcare through cutting-edge genomic solutions like MSIcare. We believe that innovation in microsatellite instability (MSI) testing plays a crucial role in transforming patient outcomes and personalizing treatment options. We want to hear from you! 🌍 Take part in our poll and let us know your thoughts on MSI testing and its impact on personalized treatment plans. Your insights will help us continue pushing personalized medicine's boundaries and refine our solutions. 👇 Cast your vote now! 👇 #MSI #PersonalizedMedicine #GenomicTesting #HealthcareInnovation #Biomarkers #MSInsight #MSICare #FutureOfHealthcare #Poll
Ce contenu n’est pas disponible ici
Accédez à ce contenu et plus encore dans l’application LinkedIn
-
🌟 Celebrating Growth: Welcoming Mélyna K. as Our New QA/RA Specialist! 🎉 We’re excited to welcome Mélyna to the team full-time as our Quality Assurance/Regulatory Affairs Specialist after a successful year as an intern! Mélyna recently graduated from ISIFC (Institut Supérieur d'Ingénieurs de Franche-Comté), where she gained expertise in: 🔹 Regulatory Affairs & Quality Assurance (MDR, IVDR, FDA, ISO 13485) 🔹 Programming & Electronics (Python, Java, C coding) 🔹 eHealth & AI Her skills and commitment will be invaluable as we continue growing. Congrats, Mélyna! 👏 #MSInsightTeam #QARA #BiomedicalEngineering #NewChapter #ISIFC
-